Gastrointestinal Hemorrhage with MCC DRG Reimbursement

DRG 377 addresses inpatient admissions for gastrointestinal hemorrhage with a Major Complication or Comorbidity, encompassing severe bleeding events that demand elevated resource use for stabilization and therapeutic procedures. It matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity elevates the Diagnosis-Related Group assignment and corresponding Medicare payment compared with less complex hemorrhage cases.

DRG 377 Overview

DRG 377 covers inpatient stays for patients with gastrointestinal hemorrhage accompanied by a Major Complication or Comorbidity. Cases typically involve significant bleeding from the upper or lower gastrointestinal tract that requires hospitalization for stabilization, endoscopic intervention, transfusion, or intensive monitoring. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity increases resource use and impacts reimbursement relative to less complex gastrointestinal hemorrhage cases. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and the associated payment level.

Acute hemostatic intervention trials: randomized or prospective studies testing endoscopic, interventional radiology, or pharmacologic strategies to achieve rapid control of gastrointestinal bleeding in hospitalized patients with hemodynamic instability or large-volume blood loss. These trials enroll patients at presentation with upper or lower GI hemorrhage, often stratified by comorbidity burden and anticoagulant use, and measure time to hemostasis, transfusion needs, rebleeding, and in-hospital mortality. Results directly inform inpatient care pathways, resource use (ICU time, blood products), and short-term cost drivers relevant to DRG 377 reimbursement and utilization management.
Comparative effectiveness studies of peri-procedural management in complex patients: observational cohorts or pragmatic randomized trials comparing approaches such as timing of endoscopy, strategies for holding or reversing anticoagulation/antiplatelet therapy, and use of risk scores to guide level-of-care decisions in older adults and patients with multiple comorbid conditions (the MCC component). These studies focus on patients with concurrent cardiac, renal, or hepatic disease who are at higher risk for recurrent bleeding or procedural complications, evaluating outcomes like rebleeding, thrombotic events, length of stay, and readmissions. Findings help clinicians balance competing risks and help payers and hospitals develop protocols to reduce complications and avoid costly prolonged admissions or readmissions under DRG 377.
Post-discharge outcomes and care coordination research: longitudinal studies and quality-improvement trials examining interventions after hospital discharge such as structured follow-up, medication reconciliation (e.g., anticoagulant restart protocols), anemia management programs, and transitional care models to reduce 30-day readmissions and late rebleeding. These studies target survivors of an index GI hemorrhage admission, particularly those discharged with unresolved anemia or on chronic anticoagulation, and track patient-centered outcomes, outpatient utilization, and total episode costs. This area is relevant to providers and payers because reducing avoidable readmissions and downstream complications can improve patient outcomes and lower aggregate expenditures associated with DRG 377 episodes of care.

Acute hemostatic intervention trials: randomized or prospective studies testing endoscopic, interventional radiology, or pharmacologic strategies to achieve rapid control of gastrointestinal bleeding in hospitalized patients with hemodynamic instability or large-volume blood loss. These trials enroll patients at presentation with upper or lower GI hemorrhage, often stratified by comorbidity burden and anticoagulant use, and measure time to hemostasis, transfusion needs, rebleeding, and in-hospital mortality. Results directly inform inpatient care pathways, resource use (ICU time, blood products), and short-term cost drivers relevant to DRG 377 reimbursement and utilization management.
Comparative effectiveness studies of peri-procedural management in complex patients: observational cohorts or pragmatic randomized trials comparing approaches such as timing of endoscopy, strategies for holding or reversing anticoagulation/antiplatelet therapy, and use of risk scores to guide level-of-care decisions in older adults and patients with multiple comorbid conditions (the MCC component). These studies focus on patients with concurrent cardiac, renal, or hepatic disease who are at higher risk for recurrent bleeding or procedural complications, evaluating outcomes like rebleeding, thrombotic events, length of stay, and readmissions. Findings help clinicians balance competing risks and help payers and hospitals develop protocols to reduce complications and avoid costly prolonged admissions or readmissions under DRG 377.
Post-discharge outcomes and care coordination research: longitudinal studies and quality-improvement trials examining interventions after hospital discharge such as structured follow-up, medication reconciliation (e.g., anticoagulant restart protocols), anemia management programs, and transitional care models to reduce 30-day readmissions and late rebleeding. These studies target survivors of an index GI hemorrhage admission, particularly those discharged with unresolved anemia or on chronic anticoagulation, and track patient-centered outcomes, outpatient utilization, and total episode costs. This area is relevant to providers and payers because reducing avoidable readmissions and downstream complications can improve patient outcomes and lower aggregate expenditures associated with DRG 377 episodes of care.

OpenPayer

Summary & Overview

Gastrointestinal Hemorrhage with MCC: Inpatient Reimbursement Overview

DRG 377 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes